Metraipolis › archive › dc_87d563d985e6
Efficacy, safety, and biomarkers of neoadjuvant trastuzumab and pertuzumab combined with chemotherapy in Chinese patients with HER2-positive breast cancer: a… — Europe PMC PMID:41056055
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41056055
- DOI
- 10.1097/js9.0000000000003551
- License (as archived)
- solo-consultazione
- Archived
- 2026-10-06T08:18:10.820Z
- SHA-256 of the archived text
a2cc0219730c58850f14c0b31be5bf562c82a111d9291c05b3f3cfa3fa72096a- Stable URL of this page
https://metraipolis.com/documento/dc_87d563d985e6
How to cite
Efficacy, safety, and biomarkers of neoadjuvant trastuzumab and pertuzumab combined with chemotherapy in Chinese patients with HER2-positive breast cancer: a… — Europe PMC PMID:41056055 — Europe PMC (en), https://europepmc.org/article/MED/41056055 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_87d563d985e6 (Metraipolis archive dc_87d563d985e6, sha256 a2cc0219730c58850f14c0b31be5bf562c82a111d9291c05b3f3cfa3fa72096a)
BibTeX
@misc{dc87d563d985e6,
title = {Efficacy, safety, and biomarkers of neoadjuvant trastuzumab and pertuzumab combined with chemotherapy in Chinese patients with HER2-positive breast cancer: a… — Europe PMC PMID:41056055},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41056055},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_87d563d985e6; sha256 a2cc0219730c58850f14c0b31be5bf562c82a111d9291c05b3f3cfa3fa72096a},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41056055. Agents can read the archived copy with the MCP tool read_document.